Skip to content
OpenCapital
Get started

Upstream Bio, Inc. UPB Cash & Equivalents

Cash & Equivalents at other companies

Amgen logo
AmgenAMGN
$559M+10.0%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$2.97B-4.0%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$28.66M-5.6%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$90.42M+48.5%
Savara logo
SavaraSVRA
$38.79M+98.4%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$248.47M+152%

Other financials

Income statement

See full
Revenue$1.0M+82.7%
Operating income-$43.6M-36.2%
Net income-$40.6M-48.8%
EPS (diluted)-$0.75-47.1%

Balance sheet

See full
Total debt$1.1M-34.5%
Total equity$304.0M-31.8%
Total assets$318.1M-30.3%

Cash flow

See full
Operating cash flow-$47.9M-16.2%
CapEx$54.0K-70.8%
Free cash flow-$30.7M-55.0%

Valuation

See full
Market cap$346.11M-40.9%
Enterprise value$250.5M-51.4%
P/S104.2×-151×

Profitability

See full
Operating margin-5,176.5%+1,764pp
Net margin-4,719%+2,752pp

Returns & leverage

See full
Return on equity-41.8%—
Debt / equity0×0.0×
Current ratio23.1×-24.3×

Where this comes from

Reported directly by Upstream Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Upstream Bio, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Upstream Bio, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Upstream Bio, Inc.'s cash & equivalents?
Upstream Bio, Inc. (UPB) reported cash & equivalents of $96.72M in Q1 2026.
How has Upstream Bio, Inc.'s cash & equivalents changed year-over-year?
Upstream Bio, Inc.'s cash & equivalents increased by 35.6% year-over-year, from $71.31M to $96.72M.
What is the long-term trend for Upstream Bio, Inc.'s cash & equivalents?
Over 2 years (2023 to 2025), Upstream Bio, Inc.'s cash & equivalents has grown at a 98.3% compound annual growth rate (CAGR), from $25.83M to $101.58M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.